heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer

Autor: Kuemmel, Sherko^1,2 (AUTHOR), Harper-Wynne, Catherine³ (AUTHOR), Park, Yeon Hee⁴ (AUTHOR), Franke, Fábio⁵ (AUTHOR), de Laurentiis, Michelino⁶ (AUTHOR), Schumacher-Wulf, Eva⁷ (AUTHOR), Eiger, Daniel⁸ (AUTHOR), Heeson, Sarah⁹ (AUTHOR), Cardona, Andrés⁸ (AUTHOR), Özyilkan, Özgür¹⁰ (AUTHOR), Morales-Vàsquez, Flavia¹¹ (AUTHOR), Metcalfe, Ciara¹² (AUTHOR), Hafner, Marc¹² (AUTHOR), Restuccia, Eleonora⁸ (AUTHOR), O'Shaughnessy, Joyce¹³ (AUTHOR) Joyce.OShaughnessy@usoncology.com

Publikováno v: BMC Cancer. 5/24/2024, Vol. 24 Issue 1, p1-14. 14p.

A Double-blind Randomized Comparative Phase I Study to Assess Biosimilarity and Immunogenicity of 'Trastuzumab' (LLC 'Mabscale', Russia) and Herceptin® (F. Hoffmann-La Roche Ltd., Switzerland) in Healthy Volunteers

Autor: M. A. Kolganova, E. E. Beketov, V. V. Pisarev, A. V. Ivanov, S. V. Vasiliev, I. E. Shokhin

Publikováno v: Разработка и регистрация лекарственных средств, Vol 12, Iss 3, Pp 240-249 (2023)

Introduction. Trastuzumab is the first drug based on the monoclonal antibodies’ technology targeted to the neu oncogene expression product discovered in the middle 80-s – human epidermal growth receptor, HER2. After being approved trastuzumab had

Externí odkaz: https://doaj.org/article/60567173043c4434badf112989e98f06

F. Hoffmann-La Roche Ltd SWOT Analysis.

Publikováno v: F. Hoffmann-La Roche Ltd. SWOT Analysis. 12/14/2022, p1-7. 7p.

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.

Autor: Pérez-García, José Manuel^1,2 (AUTHOR), Cortés, Javier^1,2,3 (AUTHOR), Ruiz-Borrego, Manuel⁴ (AUTHOR), Colleoni, Marco⁵ (AUTHOR), Stradella, Agostina⁶ (AUTHOR), Bermejo, Begoña^7,8,9 (AUTHOR), Dalenc, Florence¹⁰ (AUTHOR), Escrivá-de-Romaní, Santiago¹¹ (AUTHOR), Calvo Martínez, Lourdes¹² (AUTHOR), Ribelles, Nuria¹³ (AUTHOR), Marmé, Frederik¹⁴ (AUTHOR), Cortés, Alfonso¹⁵ (AUTHOR), Albacar, Cinta¹⁶ (AUTHOR), Gebhart, Geraldine¹⁷ (AUTHOR), Prat, Aleix^18,19,20 (AUTHOR), Kerrou, Khaldoun^21,22 (AUTHOR), Schmid, Peter^23,24 (AUTHOR), Braga, Sofia^25,26 (AUTHOR), Di Cosimo, Serena²⁷ (AUTHOR), Gion, Maria¹⁵ (AUTHOR)

Publikováno v: Lancet. 4/27/2024, Vol. 403 Issue 10437, p1649-1659. 11p.

DATAMONITOR: F. Hoffmann-La Roche Ltd.

Publikováno v: Roche Group SWOT Analysis. Jul2011, p1-8. 8p.